Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy
- PMID: 28834411
- DOI: 10.1002/acr.23347
Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy
Abstract
Objective: In real life, in a substantial proportion of gouty patients receiving urate-lowering therapy (ULT), urate levels are not maintained below the target of 6.0 mg/dl. We aimed to search for factors associated with poor control of serum uric acid (UA) levels in a large population of patients with gout receiving ULT.
Methods: This cross-sectional study involved adults with gout in primary care who were receiving ULT. Demographics, gout history, comorbidities, lifestyle, clinical factors, concomitant treatments, and laboratory data were compared in well-controlled gout (serum UA ≤6.0 mg/dl) versus poorly controlled gout (serum UA >6.0 mg/dl) on univariate and multivariate analyses.
Results: Among the 1,995 patients receiving ULT, only 445 (22.3%) had reached the target of 6.0 mg/dl serum UA. Such patients had a lower rate of gout flares within the previous year than patients without the target (mean ± SD 1.7 ± 1.4 versus 2.1 ± 1.4; P < 0.0001). The main factors associated with poor serum UA level control in multivariate analysis were low high-density lipoprotein cholesterol level (adjusted odds ratio [OR] 0.5 [95% confidence interval (95% CI) 0.26-0.96]; P = 0.04), high total cholesterol level (OR 1.83 [95% CI 1.29-2.60]; P = 0.0007), increased waist circumference (OR 1.55 [95% CI 1.11-2.13]; P = 0.008), and alcohol consumption (OR 1.52 [95% CI 1.15-2.00]; P = 0.003).
Conclusion: Dyslipidemia, abdominal obesity, and alcohol consumption are the main factors associated with a poor response to ULT. Knowledge of these factors might help physicians identify cases of gout that may be less likely to achieve target urate level.
© 2017, American College of Rheumatology.
Similar articles
-
Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.Clin Rheumatol. 2019 Dec;38(12):3511-3519. doi: 10.1007/s10067-019-04737-5. Epub 2019 Aug 13. Clin Rheumatol. 2019. PMID: 31410659 Clinical Trial.
-
Gout, urate-lowering therapy, and uric acid levels among adults in the United States.Arthritis Care Res (Hoboken). 2015 Apr;67(4):588-92. doi: 10.1002/acr.22469. Arthritis Care Res (Hoboken). 2015. PMID: 25201123 Free PMC article.
-
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.BMC Nephrol. 2024 Aug 20;25(1):266. doi: 10.1186/s12882-024-03712-w. BMC Nephrol. 2024. PMID: 39164615 Free PMC article.
-
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2. Curr Rheumatol Rep. 2018. PMID: 29931553 Review.
-
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.J Gen Intern Med. 2018 Mar;33(3):358-366. doi: 10.1007/s11606-017-4233-5. Epub 2017 Dec 4. J Gen Intern Med. 2018. PMID: 29204974 Free PMC article.
Cited by
-
Korean guidelines for the management of gout.Korean J Intern Med. 2023 Sep;38(5):641-650. doi: 10.3904/kjim.2023.206. Epub 2023 Aug 28. Korean J Intern Med. 2023. PMID: 37635283 Free PMC article.
-
Healthy lifestyle counteracts the risk effect of genetic factors on incident gout: a large population-based longitudinal study.BMC Med. 2022 Apr 29;20(1):138. doi: 10.1186/s12916-022-02341-0. BMC Med. 2022. PMID: 35484537 Free PMC article.
-
Association between patient adherence and treat-to-target in gout: A cross-sectional study.Medicine (Baltimore). 2024 Feb 23;103(8):e37228. doi: 10.1097/MD.0000000000037228. Medicine (Baltimore). 2024. PMID: 38394537 Free PMC article.
-
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.RMD Open. 2023 Dec 1;9(4):e003600. doi: 10.1136/rmdopen-2023-003600. RMD Open. 2023. PMID: 38053463 Free PMC article.
-
Patient considerations in the management of gout and role of combination treatment with lesinurad.Patient Relat Outcome Meas. 2018 Jul 18;9:231-238. doi: 10.2147/PROM.S108868. eCollection 2018. Patient Relat Outcome Meas. 2018. PMID: 30140163 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical